Frank Neumann, M.D., Ph.D.

Dr. Frank Neumann is an Entrepreneur Partner at MPM BioImpact and Chief Medical Officer of Orna Therapeutics, an MPM BioImpact portfolio company. Frank brings extensive experience and proven leadership in cell therapy and oncology clinical development to these roles.

Prior to joining MPM BioImpact, Frank served as Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company. Previously Frank held positions as Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, he was clinical development head of global cell therapy approaches at Takeda Pharmaceuticals, where he also held various leadership roles of increasing prominence including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, Frank was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.

Board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine, Frank was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany, where he received his M.D. He earned his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany.